View Financial HealthNephros 배당 및 자사주 매입배당 기준 점검 0/6Nephros 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.8%자사주 매입 수익률총 주주 수익률-0.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • 20hNew minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.5m market cap).분석 기사 • May 11Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Lifting Their Price TargetsIt's been a pretty great week for Nephros, Inc. ( NASDAQ:NEPH ) shareholders, with its shares surging 15% to US$3.52 in...Reported Earnings • May 11First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2026 results: EPS: US$0.013 (down from US$0.053 in 1Q 2025). Revenue: US$5.21m (up 6.9% from 1Q 2025). Net income: US$140.0k (down 75% from 1Q 2025). Profit margin: 2.7% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.공지 • May 02Nephros, Inc. to Report Q1, 2026 Results on May 07, 2026Nephros, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026분석 기사 • Apr 29Is Nephros, Inc. (NASDAQ:NEPH) Potentially Undervalued?Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it saw a decent share price growth of 19% on the...Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$3.32, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Machinery industry in the US. Total returns to shareholders of 134% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$6.38 per share.공지 • Apr 01Nephros Inc Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseNephros, Inc. announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros’ ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs). This new capability marks a meaningful extension of Nephros’ field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service. Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company’s perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges.Valuation Update With 7 Day Price Move • Mar 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$2.95, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 194% over the past three years.Reported Earnings • Mar 15Full year 2025 earnings: EPS in line with analyst expectations despite revenue beatFull year 2025 results: EPS: US$0.11 (up from US$0.007 in FY 2024). Revenue: US$18.8m (up 33% from FY 2024). Net income: US$1.19m (up US$1.12m from FY 2024). Profit margin: 6.4% (up from 0.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.공지 • Mar 05Nephros, Inc. to Report Q4, 2025 Results on Mar 12, 2026Nephros, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.87, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Machinery industry in the US. Total returns to shareholders of 234% over the past three years.분석 기사 • Feb 06Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28%Nephros, Inc. ( NASDAQ:NEPH ) shareholders won't be pleased to see that the share price has had a very rough month...Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$4.54, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 20x in the Machinery industry in the US. Total returns to shareholders of 269% over the past three years.분석 기사 • Jan 07Is It Time To Consider Buying Nephros, Inc. (NASDAQ:NEPH)?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it received a lot of attention from a...분석 기사 • Dec 13Nephros (NASDAQ:NEPH) Is Experiencing Growth In Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$5.79, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 473% over the past three years.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$4.42, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 344% over the past three years.Reported Earnings • Nov 09Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$0.032 (up from US$0.017 in 3Q 2024). Revenue: US$4.76m (up 35% from 3Q 2024). Net income: US$337.0k (up 84% from 3Q 2024). Profit margin: 7.1% (up from 5.2% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth.공지 • Oct 31Nephros, Inc. to Report Q3, 2025 Results on Nov 06, 2025Nephros, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to US$5.74, the stock trades at a forward P/E ratio of 109x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 447% over the past three years.공지 • Oct 09Nephros, Inc. Launches New Pfas Filter for Point-Of-Use Protection of Potable WaterNephros, Inc. announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros' portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as "forever chemicals," are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. Key Features of the Nephros 19-Series PFAS Filter: Independently tested to NSF Standards 42 and 53; Validated reduction of Total PFAS, including PFOA and PFOS; Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor; 3,145-gallon capacity with a 1.63 GPM flow rate; Provides long-term protection against persistent, health-threatening waterborne contaminants.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$5.44, the stock trades at a forward P/E ratio of 104x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 467% over the past three years.분석 기사 • Oct 01Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price SurgeNephros, Inc. ( NASDAQ:NEPH ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Sep 13At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it saw a significant share price rise of 47...New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 55% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 55% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$45.2m market cap).New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$41.3m market cap).Reported Earnings • Aug 10Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.022 (up from US$0.027 loss in 2Q 2024). Revenue: US$4.42m (up 36% from 2Q 2024). Net income: US$237.0k (up US$526.0k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.분석 기사 • Aug 07It's Down 26% But Nephros, Inc. (NASDAQ:NEPH) Could Be Riskier Than It LooksNasdaqCM:NEPH 1 Year Share Price vs Fair Value Explore Nephros's Fair Values from the Community and select yours...Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.00, the stock trades at a forward P/E ratio of 481x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 69% over the past three years.공지 • Aug 01Nephros, Inc. to Report Q2, 2025 Results on Aug 07, 2025Nephros, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$5.00, the stock trades at a forward P/E ratio of 802x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$7.93 per share.공지 • Jun 19Nephros, Inc. Approves Election of Lisa Nettis as DirectorNephros, Inc. announced at the AGM held on June 16, 2025, approved Lisa Nettis as director, to serve a three-year term expiring in 2028.분석 기사 • Jun 16Nephros, Inc.'s (NASDAQ:NEPH) 79% Jump Shows Its Popularity With InvestorsDespite an already strong run, Nephros, Inc. ( NASDAQ:NEPH ) shares have been powering on, with a gain of 79% in the...Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$3.40, the stock trades at a forward P/E ratio of 545x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 89% over the past three years.New Risk • Jun 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$28.8m market cap).Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$2.63, the stock trades at a forward P/E ratio of 422x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 51% over the past three years.분석 기사 • May 14Should You Think About Buying Nephros, Inc. (NASDAQ:NEPH) Now?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it led the NASDAQCM gainers with a relatively...New Risk • May 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 151% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$22.0m market cap).Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.026 (up from US$0.016 loss in 1Q 2024). Revenue: US$4.88m (up 39% from 1Q 2024). Net income: US$558.0k (up US$727.0k from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공지 • May 01Nephros, Inc., Annual General Meeting, Jun 16, 2025Nephros, Inc., Annual General Meeting, Jun 16, 2025. Location: virtualshareholdermeeting.com/neph2025, United States분석 기사 • Apr 18Investors Still Aren't Entirely Convinced By Nephros, Inc.'s (NASDAQ:NEPH) Revenues Despite 32% Price JumpNephros, Inc. ( NASDAQ:NEPH ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Reported Earnings • Mar 07Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: US$0.007 (up from US$0.15 loss in FY 2023). Revenue: US$14.2m (flat on FY 2023). Net income: US$74.0k (up US$1.65m from FY 2023). Profit margin: 0.5% (up from net loss in FY 2023). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.New Risk • Nov 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$2.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$2.2m free cash flow). Minor Risk Market cap is less than US$100m (US$16.2m market cap).Reported Earnings • Nov 10Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.017 (up from US$0.017 loss in 3Q 2023). Revenue: US$3.52m (down 6.0% from 3Q 2023). Net income: US$183.0k (up US$365.0k from 3Q 2023). Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공지 • Oct 31Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nephros, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024공지 • Oct 25Nephros, Inc. Launches New HydraGuard 20" UltraFilterNephros, Inc. announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards. The HydraGuard 20" filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST 108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes.분석 기사 • Oct 03It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)There wouldn't be many who think Nephros, Inc.'s ( NASDAQ:NEPH ) price-to-sales (or "P/S") ratio of 1.2x is worth a...Major Estimate Revision • Aug 23Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$13.6m to US$14.0m. EPS estimate increased from -US$0.09 per share to -US$0.08 per share. Machinery industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$4.75 unchanged from last update. Share price was steady at US$1.84 over the past week.Reported Earnings • Aug 11Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.027 loss per share (improved from US$0.042 loss in 2Q 2023). Revenue: US$3.25m (down 8.3% from 2Q 2023). Net loss: US$289.0k (loss narrowed 33% from 2Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.공지 • Aug 01Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024Nephros, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024분석 기사 • Jul 14We're Not Worried About Nephros' (NASDAQ:NEPH) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...Recent Insider Transactions • May 17President recently bought US$112k worth of stockOn the 16th of May, Robert Banks bought around 50k shares on-market at roughly US$2.24 per share. This transaction increased Robert's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Robert has been a buyer over the last 12 months, purchasing a net total of US$152k worth in shares.Major Estimate Revision • May 16Consensus EPS estimates upgraded to US$0.035 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.7m to US$16.0m. 2024 losses expected to reduce from -US$0.065 to -US$0.035 per share. Consumer Durables industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$4.75 unchanged from last update. Share price rose 2.5% to US$2.27 over the past week.분석 기사 • May 13Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their EstimatesShareholders might have noticed that Nephros, Inc. ( NASDAQ:NEPH ) filed its quarterly result this time last week. The...Reported Earnings • May 13First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.016 loss per share (improved from US$0.03 loss in 1Q 2023). Revenue: US$3.52m (down 4.7% from 1Q 2023). Net loss: US$169.0k (loss narrowed 45% from 1Q 2023). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 50%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.공지 • Apr 14Nephros, Inc., Annual General Meeting, May 23, 2024Nephros, Inc., Annual General Meeting, May 23, 2024, at 10:00 US Eastern Standard Time. Location: 380 Lackawanna Place South Orange New Jersey United States Agenda: to Elect two directors to serve a three-year term expiring in 2027; Ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; Approve the 2024 Equity Incentive Plan; Approve the compensation of the Company’s named executive officers on an advisory (non-binding) basis; and Act upon such other matters as may properly come before the meeting or any adjournment thereof.Reported Earnings • Mar 10Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$0.15 loss per share (improved from US$0.44 loss in FY 2022). Revenue: US$14.2m (up 43% from FY 2022). Net loss: US$1.58m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$1.7m Forecast net loss in 1 year: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$677k net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (US$31.8m market cap).공지 • Mar 01Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024Nephros, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024Buy Or Sell Opportunity • Feb 05Now 21% undervaluedOver the last 90 days, the stock has risen 100% to US$3.60. The fair value is estimated to be US$4.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 60% in the next year.Buying Opportunity • Dec 28Now 25% undervaluedOver the last 90 days, the stock is up 136%. The fair value is estimated to be US$4.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.분석 기사 • Dec 18After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The RadarNephros, Inc. ( NASDAQ:NEPH ) shares have continued their recent momentum with a 40% gain in the last month alone. The...분석 기사 • Dec 14At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it received a lot of attention from a substantial...Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.12 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$0.13 to -US$0.115 per share. Revenue forecast steady at US$14.8m. Consumer Durables industry in the US expected to see average net income decline 3.8% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$2.10 over the past week.Major Estimate Revision • Nov 15Consensus estimates of losses per share improve by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$14.1m to US$14.8m. EPS estimate increased from -US$0.185 per share to -US$0.13 per share. Consumer Durables industry in the US expected to see average net income decline 3.7% next year. Consensus price target up from US$3.00 to US$4.50. Share price rose 16% to US$2.09 over the past week.Breakeven Date Change • Nov 10Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 96% is required to achieve expected profit on schedule.공지 • Nov 03Nephros, Inc., Hires Judy Krandel as Chief Financial OfficerNephros, Inc. announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the companys finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephross long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, investment, operations, financial reporting and oversight, as well as formal accounting expertise Prior to joining Nephros, Ms. Krandel served as the Chief Financial Officer of Recruiter.com, where she worked closely with the CEO to leverage AI and new technology to drive company growth while also building public market capitalization and enterprise value. Additionally, Ms. Krandel was responsible for developing strategies for capital allocation, internal growth, and M&A while at Paltalk, Inc. Ms. Krandel holds a Bachelor of Science in Finance from the Wharton School and a Master of Business Administration from the University of Chicago Booth School of Business. In addition to previous roles as Chief Financial Officer for two other publicly traded companies, Ms. Krandel has been simultaneously active in multiple corporate and advisory boards..공지 • Oct 26Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023Nephros, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.2m net loss next year). Share price has been volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$100m (US$19.4m market cap).New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 7.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 7.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$15.8m market cap).공지 • Jul 28Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023Nephros, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023New Risk • Jun 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.4m net loss next year). Market cap is less than US$100m (US$19.4m market cap).Breakeven Date Change • May 12No longer forecast to breakevenThe analyst covering Nephros no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$41.0k in 2024. New forecast suggests the company will make a loss of US$121.0k in 2024.Reported Earnings • May 11First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: US$0.03 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$3.70m (up 69% from 1Q 2022). Net loss: US$306.0k (loss narrowed 85% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 2.4% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.공지 • May 09+ 1 more updateNephros, Inc. Announces CEO ChangesNephros, Inc. announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros’ Form 10-Q for the quarter ended March 31, 2023. Mr. Banks is also expected to be appointed to the Nephros Board of Directors. Andy Astor will remain with Nephros as an advisor to Mr. Banks and as interim Chief Financial Officer (CFO), while a search is conducted for a permanent CFO. As part of the transition, Mr. Astor will step down from the board of directors. Mr. Banks has a proven track record of delivering value through innovation and aligning the strengths of his organizations with customer needs to drive profitable growth. He spent nearly 20 years at GE, where he held a variety of commercial and engineering roles with small- and medium-sized business units. After GE, he was Executive Director of Product Management at ITT Corporation, where he was responsible for sales and marketing of a leading commercial pump portfolio. Most recently, Mr. Banks was Vice President of Global Strategic Accounts at Danfoss Power Solutions.Breakeven Date Change • Apr 06Forecast to breakeven in 2024The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 55% to 2023. The company is expected to make a profit of US$41.0k in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 15Consensus EPS estimates fall by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$12.8m to US$11.5m. Losses expected to increase from US$0.15 per share to US$0.20. Consumer Durables industry in the US expected to see average net income decline 33% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 8.8% to US$1.03 over the past week.Reported Earnings • Mar 10Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$0.44 loss per share (further deteriorated from US$0.41 loss in FY 2021). Revenue: US$9.98m (down 4.1% from FY 2021). Net loss: US$4.55m (loss widened 11% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.Price Target Changed • Feb 15Price target decreased by 27% to US$3.00Down from US$4.13, the current price target is provided by 1 analyst. New target price is 150% above last closing price of US$1.20. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$0.69 next year compared to a net loss per share of US$0.41 last year.Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Alisa Lask was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공지 • Feb 04Nephros, Inc. Announces Board ChangesOn January 30, 2023, Thomas Gwydir resigned from the board of directors of Nephros, Inc., effective February 1, 2023. On February 2, 2023, the company’s board of directors appointed Alisa Lask to serve as a member of its Audit Committee, filling the vacancy created by Mr. Gwydir’s resignation.공지 • Jan 12+ 1 more updateNephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023Nephros, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 08, 2023공지 • Nov 16Nephros, Inc. announced delayed 10-Q filingOn 11/15/2022, Nephros, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Price Target Changed • Nov 16Price target decreased to US$3.63Down from US$4.13, the current price target is an average from 2 analysts. New target price is 241% above last closing price of US$1.06. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.63 next year compared to a net loss per share of US$0.41 last year.Major Estimate Revision • Nov 09Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$10.5m to US$10.3m. Losses expected to increase from US$0.51 per share to US$0.63. Consumer Durables industry in the US expected to see average net income decline 15% next year. Consensus price target of US$3.63 unchanged from last update. Share price was steady at US$1.04 over the past week.Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.13 loss per share (further deteriorated from US$0.12 loss in 3Q 2021). Revenue: US$2.41m (down 8.6% from 3Q 2021). Net loss: US$1.33m (loss widened 8.6% from 3Q 2021). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 182%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.공지 • Oct 12+ 2 more updatesNephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022Nephros, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022Seeking Alpha • Sep 28Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operationNephros (NASDAQ:NEPH) has shipped 3,000 commercial water filters as part of its ongoing annual contract with Donastar Enterprises and Tractor Beverage in service of a national chain of fast-casual restaurants. “Earlier this year we established ourselves as an approved vendor for a national and widely recognized Quick Service Restaurant chain. The completion of this initial delivery is an important milestone in our continuing relationship, and a marker of success for the Nephros commercial water filtration business. The initial results of our partnerships with Donastar and Tractor are indicative of both positive momentum and high potential for additional national contracts. We look forward to developing even greater opportunities as our business relationships progress.” said Andy Astor, President and Chief Executive Officer.공지 • Sep 10Nephros Appoints Joe Harris to Its Board of DirectorsNephros, Inc. announced the appointment of Joe Harris to its Board of Directors. Joe Harris is currently the Midwest, Sales Director at Murj. Previous positions have included East, Areas Sales Director at HeartFlow, Inc., Midwest Regional Sales Director at BIOTRONIK, and Regional Sales Manager at Boston Scientific. Joe is also a U.S. Army veteran. He received his B.S. in Systems Engineering Economics from the United States Military Academy at West Point, and his MBA in Marketing Finance from the University of Michigan.공지 • Aug 24Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022On August 17, 2022, Wes Lobo, Chief Commercial Officer of Nephros, Inc. notified the Company that he is resigning his employment with the Company, to be effective no later than September 30, 2022.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NEPH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NEPH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Nephros 배당 수익률 vs 시장NEPH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NEPH)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Machinery)1.1%분석가 예측 (NEPH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NEPH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NEPH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NEPH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NEPH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 20:12종가2026/05/11 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nephros, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert WassermanBenchmark CompanyMarc WiesenbergerB. Riley Securities, Inc.Anthony VendettiMaxim Group
New Risk • 20hNew minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.5m market cap).
분석 기사 • May 11Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Lifting Their Price TargetsIt's been a pretty great week for Nephros, Inc. ( NASDAQ:NEPH ) shareholders, with its shares surging 15% to US$3.52 in...
Reported Earnings • May 11First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2026 results: EPS: US$0.013 (down from US$0.053 in 1Q 2025). Revenue: US$5.21m (up 6.9% from 1Q 2025). Net income: US$140.0k (down 75% from 1Q 2025). Profit margin: 2.7% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.
공지 • May 02Nephros, Inc. to Report Q1, 2026 Results on May 07, 2026Nephros, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
분석 기사 • Apr 29Is Nephros, Inc. (NASDAQ:NEPH) Potentially Undervalued?Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it saw a decent share price growth of 19% on the...
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$3.32, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Machinery industry in the US. Total returns to shareholders of 134% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$6.38 per share.
공지 • Apr 01Nephros Inc Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseNephros, Inc. announced an expansion of its customer-facing, water-safety support capabilities following the ASSE 12080 Legionella Water Safety and Management Specialist Certification earned by Brianne McGuire, Director of Business Development. The certification strengthens Nephros’ ability to provide consultative support to healthcare facilities and other complex buildings seeking to reduce waterborne pathogen risk and adds specific proficiency in the development of effective Water Management Programs (WMPs). This new capability marks a meaningful extension of Nephros’ field support for customers seeking more robust water safety programs. In addition to point-of-use filtration solutions, product installations and replacements, as well as public education, Nephros can now provide a direct Water Management Program development service. Water Management Programs offer a structured framework for identifying water-quality risks, establishing control measures, assigning responsibility, and defining ongoing monitoring and response. The company believes this offering will create additional value for customers while opening a new avenue for revenue generation through chargeable consulting service. Nephros considers this support expansion to be differentiated by the depth of practical knowledge informing it. Besides the new ASSE 12080 certification, Ms. McGuire brings broad experience in technical concerns, waterborne risk, current guidance and standards, and industry best practices born out of direct engagement with healthcare facilities and other regulated environments. Her leadership of the Nephros Water Institute and other company public education initiatives has further expanded the company’s perspective on how complex water safety risks are understood and addressed in practice. As a result, Nephros believes it is well-positioned to apply a diverse scope of understanding to the design of WMPs informed by extensive practical expertise in risk, implementation and real-world operational challenges.
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$2.95, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 194% over the past three years.
Reported Earnings • Mar 15Full year 2025 earnings: EPS in line with analyst expectations despite revenue beatFull year 2025 results: EPS: US$0.11 (up from US$0.007 in FY 2024). Revenue: US$18.8m (up 33% from FY 2024). Net income: US$1.19m (up US$1.12m from FY 2024). Profit margin: 6.4% (up from 0.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
공지 • Mar 05Nephros, Inc. to Report Q4, 2025 Results on Mar 12, 2026Nephros, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.87, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Machinery industry in the US. Total returns to shareholders of 234% over the past three years.
분석 기사 • Feb 06Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28%Nephros, Inc. ( NASDAQ:NEPH ) shareholders won't be pleased to see that the share price has had a very rough month...
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$4.54, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 20x in the Machinery industry in the US. Total returns to shareholders of 269% over the past three years.
분석 기사 • Jan 07Is It Time To Consider Buying Nephros, Inc. (NASDAQ:NEPH)?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it received a lot of attention from a...
분석 기사 • Dec 13Nephros (NASDAQ:NEPH) Is Experiencing Growth In Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$5.79, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 473% over the past three years.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$4.42, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 344% over the past three years.
Reported Earnings • Nov 09Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: US$0.032 (up from US$0.017 in 3Q 2024). Revenue: US$4.76m (up 35% from 3Q 2024). Net income: US$337.0k (up 84% from 3Q 2024). Profit margin: 7.1% (up from 5.2% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth.
공지 • Oct 31Nephros, Inc. to Report Q3, 2025 Results on Nov 06, 2025Nephros, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to US$5.74, the stock trades at a forward P/E ratio of 109x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 447% over the past three years.
공지 • Oct 09Nephros, Inc. Launches New Pfas Filter for Point-Of-Use Protection of Potable WaterNephros, Inc. announced the launch of its new filter designed to reduce Total PFAS, or per- and polyfluoroalkyl substances (PFAS), in potable water. This product expands Nephros' portfolio to address a category of chemical contaminants that have drawn growing regulatory and public health attention. PFAS, sometimes referred to as "forever chemicals," are synthetic compounds found in a wide range of consumer and industrial products. They are notable for their persistence in the environment, as well as their bioaccumulative nature and risk to human health. Key Features of the Nephros 19-Series PFAS Filter: Independently tested to NSF Standards 42 and 53; Validated reduction of Total PFAS, including PFOA and PFOS; Effectively reduces other hazardous contaminants such as lead, asbestos, cysts, chlorine, taste, and odor; 3,145-gallon capacity with a 1.63 GPM flow rate; Provides long-term protection against persistent, health-threatening waterborne contaminants.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$5.44, the stock trades at a forward P/E ratio of 104x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 467% over the past three years.
분석 기사 • Oct 01Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price SurgeNephros, Inc. ( NASDAQ:NEPH ) shareholders would be excited to see that the share price has had a great month, posting...
분석 기사 • Sep 13At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it saw a significant share price rise of 47...
New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 55% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 55% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$45.2m market cap).
New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$41.3m market cap).
Reported Earnings • Aug 10Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.022 (up from US$0.027 loss in 2Q 2024). Revenue: US$4.42m (up 36% from 2Q 2024). Net income: US$237.0k (up US$526.0k from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
분석 기사 • Aug 07It's Down 26% But Nephros, Inc. (NASDAQ:NEPH) Could Be Riskier Than It LooksNasdaqCM:NEPH 1 Year Share Price vs Fair Value Explore Nephros's Fair Values from the Community and select yours...
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$3.00, the stock trades at a forward P/E ratio of 481x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 69% over the past three years.
공지 • Aug 01Nephros, Inc. to Report Q2, 2025 Results on Aug 07, 2025Nephros, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$5.00, the stock trades at a forward P/E ratio of 802x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$7.93 per share.
공지 • Jun 19Nephros, Inc. Approves Election of Lisa Nettis as DirectorNephros, Inc. announced at the AGM held on June 16, 2025, approved Lisa Nettis as director, to serve a three-year term expiring in 2028.
분석 기사 • Jun 16Nephros, Inc.'s (NASDAQ:NEPH) 79% Jump Shows Its Popularity With InvestorsDespite an already strong run, Nephros, Inc. ( NASDAQ:NEPH ) shares have been powering on, with a gain of 79% in the...
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$3.40, the stock trades at a forward P/E ratio of 545x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 89% over the past three years.
New Risk • Jun 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$28.8m market cap).
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to US$2.63, the stock trades at a forward P/E ratio of 422x. Average forward P/E is 19x in the Machinery industry in the US. Total returns to shareholders of 51% over the past three years.
분석 기사 • May 14Should You Think About Buying Nephros, Inc. (NASDAQ:NEPH) Now?Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it led the NASDAQCM gainers with a relatively...
New Risk • May 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 151% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 151% per year for the foreseeable future. Minor Risk Market cap is less than US$100m (US$22.0m market cap).
Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.026 (up from US$0.016 loss in 1Q 2024). Revenue: US$4.88m (up 39% from 1Q 2024). Net income: US$558.0k (up US$727.0k from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공지 • May 01Nephros, Inc., Annual General Meeting, Jun 16, 2025Nephros, Inc., Annual General Meeting, Jun 16, 2025. Location: virtualshareholdermeeting.com/neph2025, United States
분석 기사 • Apr 18Investors Still Aren't Entirely Convinced By Nephros, Inc.'s (NASDAQ:NEPH) Revenues Despite 32% Price JumpNephros, Inc. ( NASDAQ:NEPH ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
Reported Earnings • Mar 07Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: US$0.007 (up from US$0.15 loss in FY 2023). Revenue: US$14.2m (flat on FY 2023). Net income: US$74.0k (up US$1.65m from FY 2023). Profit margin: 0.5% (up from net loss in FY 2023). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
New Risk • Nov 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$2.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$2.2m free cash flow). Minor Risk Market cap is less than US$100m (US$16.2m market cap).
Reported Earnings • Nov 10Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.017 (up from US$0.017 loss in 3Q 2023). Revenue: US$3.52m (down 6.0% from 3Q 2023). Net income: US$183.0k (up US$365.0k from 3Q 2023). Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공지 • Oct 31Nephros, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nephros, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
공지 • Oct 25Nephros, Inc. Launches New HydraGuard 20" UltraFilterNephros, Inc. announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards. The HydraGuard 20" filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST 108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes.
분석 기사 • Oct 03It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)There wouldn't be many who think Nephros, Inc.'s ( NASDAQ:NEPH ) price-to-sales (or "P/S") ratio of 1.2x is worth a...
Major Estimate Revision • Aug 23Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$13.6m to US$14.0m. EPS estimate increased from -US$0.09 per share to -US$0.08 per share. Machinery industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$4.75 unchanged from last update. Share price was steady at US$1.84 over the past week.
Reported Earnings • Aug 11Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.027 loss per share (improved from US$0.042 loss in 2Q 2023). Revenue: US$3.25m (down 8.3% from 2Q 2023). Net loss: US$289.0k (loss narrowed 33% from 2Q 2023). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Machinery industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
공지 • Aug 01Nephros, Inc. to Report Q2, 2024 Results on Aug 08, 2024Nephros, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
분석 기사 • Jul 14We're Not Worried About Nephros' (NASDAQ:NEPH) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Recent Insider Transactions • May 17President recently bought US$112k worth of stockOn the 16th of May, Robert Banks bought around 50k shares on-market at roughly US$2.24 per share. This transaction increased Robert's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Robert has been a buyer over the last 12 months, purchasing a net total of US$152k worth in shares.
Major Estimate Revision • May 16Consensus EPS estimates upgraded to US$0.035 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.7m to US$16.0m. 2024 losses expected to reduce from -US$0.065 to -US$0.035 per share. Consumer Durables industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$4.75 unchanged from last update. Share price rose 2.5% to US$2.27 over the past week.
분석 기사 • May 13Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their EstimatesShareholders might have noticed that Nephros, Inc. ( NASDAQ:NEPH ) filed its quarterly result this time last week. The...
Reported Earnings • May 13First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.016 loss per share (improved from US$0.03 loss in 1Q 2023). Revenue: US$3.52m (down 4.7% from 1Q 2023). Net loss: US$169.0k (loss narrowed 45% from 1Q 2023). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 50%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 12Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 68% to 2024. The company is expected to make a profit of US$538.0k in 2025. Average annual earnings growth of 121% is required to achieve expected profit on schedule.
공지 • Apr 14Nephros, Inc., Annual General Meeting, May 23, 2024Nephros, Inc., Annual General Meeting, May 23, 2024, at 10:00 US Eastern Standard Time. Location: 380 Lackawanna Place South Orange New Jersey United States Agenda: to Elect two directors to serve a three-year term expiring in 2027; Ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; Approve the 2024 Equity Incentive Plan; Approve the compensation of the Company’s named executive officers on an advisory (non-binding) basis; and Act upon such other matters as may properly come before the meeting or any adjournment thereof.
Reported Earnings • Mar 10Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$0.15 loss per share (improved from US$0.44 loss in FY 2022). Revenue: US$14.2m (up 43% from FY 2022). Net loss: US$1.58m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$1.7m Forecast net loss in 1 year: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$677k net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (US$31.8m market cap).
공지 • Mar 01Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024Nephros, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024
Buy Or Sell Opportunity • Feb 05Now 21% undervaluedOver the last 90 days, the stock has risen 100% to US$3.60. The fair value is estimated to be US$4.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 60% in the next year.
Buying Opportunity • Dec 28Now 25% undervaluedOver the last 90 days, the stock is up 136%. The fair value is estimated to be US$4.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 22% in a year. Earnings is forecast to grow by 60% in the next year.
분석 기사 • Dec 18After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The RadarNephros, Inc. ( NASDAQ:NEPH ) shares have continued their recent momentum with a 40% gain in the last month alone. The...
분석 기사 • Dec 14At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it received a lot of attention from a substantial...
Major Estimate Revision • Nov 21Consensus EPS estimates upgraded to US$0.12 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$0.13 to -US$0.115 per share. Revenue forecast steady at US$14.8m. Consumer Durables industry in the US expected to see average net income decline 3.8% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$2.10 over the past week.
Major Estimate Revision • Nov 15Consensus estimates of losses per share improve by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$14.1m to US$14.8m. EPS estimate increased from -US$0.185 per share to -US$0.13 per share. Consumer Durables industry in the US expected to see average net income decline 3.7% next year. Consensus price target up from US$3.00 to US$4.50. Share price rose 16% to US$2.09 over the past week.
Breakeven Date Change • Nov 10Forecast to breakeven in 2025The analyst covering Nephros expects the company to break even for the first time. New forecast suggests losses will reduce by 67% per year to 2024. The company is expected to make a profit of US$649.0k in 2025. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
공지 • Nov 03Nephros, Inc., Hires Judy Krandel as Chief Financial OfficerNephros, Inc. announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the companys finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephross long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, investment, operations, financial reporting and oversight, as well as formal accounting expertise Prior to joining Nephros, Ms. Krandel served as the Chief Financial Officer of Recruiter.com, where she worked closely with the CEO to leverage AI and new technology to drive company growth while also building public market capitalization and enterprise value. Additionally, Ms. Krandel was responsible for developing strategies for capital allocation, internal growth, and M&A while at Paltalk, Inc. Ms. Krandel holds a Bachelor of Science in Finance from the Wharton School and a Master of Business Administration from the University of Chicago Booth School of Business. In addition to previous roles as Chief Financial Officer for two other publicly traded companies, Ms. Krandel has been simultaneously active in multiple corporate and advisory boards..
공지 • Oct 26Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023Nephros, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.2m net loss next year). Share price has been volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$100m (US$19.4m market cap).
New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 7.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 7.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$15.8m market cap).
공지 • Jul 28Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023Nephros, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
New Risk • Jun 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.4m net loss next year). Market cap is less than US$100m (US$19.4m market cap).
Breakeven Date Change • May 12No longer forecast to breakevenThe analyst covering Nephros no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$41.0k in 2024. New forecast suggests the company will make a loss of US$121.0k in 2024.
Reported Earnings • May 11First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: US$0.03 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$3.70m (up 69% from 1Q 2022). Net loss: US$306.0k (loss narrowed 85% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 2.4% growth forecast for the Consumer Durables industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
공지 • May 09+ 1 more updateNephros, Inc. Announces CEO ChangesNephros, Inc. announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros’ Form 10-Q for the quarter ended March 31, 2023. Mr. Banks is also expected to be appointed to the Nephros Board of Directors. Andy Astor will remain with Nephros as an advisor to Mr. Banks and as interim Chief Financial Officer (CFO), while a search is conducted for a permanent CFO. As part of the transition, Mr. Astor will step down from the board of directors. Mr. Banks has a proven track record of delivering value through innovation and aligning the strengths of his organizations with customer needs to drive profitable growth. He spent nearly 20 years at GE, where he held a variety of commercial and engineering roles with small- and medium-sized business units. After GE, he was Executive Director of Product Management at ITT Corporation, where he was responsible for sales and marketing of a leading commercial pump portfolio. Most recently, Mr. Banks was Vice President of Global Strategic Accounts at Danfoss Power Solutions.
Breakeven Date Change • Apr 06Forecast to breakeven in 2024The 2 analysts covering Nephros expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 55% to 2023. The company is expected to make a profit of US$41.0k in 2024. Average annual earnings growth of 105% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 15Consensus EPS estimates fall by 37%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$12.8m to US$11.5m. Losses expected to increase from US$0.15 per share to US$0.20. Consumer Durables industry in the US expected to see average net income decline 33% next year. Consensus price target of US$3.00 unchanged from last update. Share price fell 8.8% to US$1.03 over the past week.
Reported Earnings • Mar 10Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$0.44 loss per share (further deteriorated from US$0.41 loss in FY 2021). Revenue: US$9.98m (down 4.1% from FY 2021). Net loss: US$4.55m (loss widened 11% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Feb 15Price target decreased by 27% to US$3.00Down from US$4.13, the current price target is provided by 1 analyst. New target price is 150% above last closing price of US$1.20. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$0.69 next year compared to a net loss per share of US$0.41 last year.
Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Alisa Lask was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공지 • Feb 04Nephros, Inc. Announces Board ChangesOn January 30, 2023, Thomas Gwydir resigned from the board of directors of Nephros, Inc., effective February 1, 2023. On February 2, 2023, the company’s board of directors appointed Alisa Lask to serve as a member of its Audit Committee, filling the vacancy created by Mr. Gwydir’s resignation.
공지 • Jan 12+ 1 more updateNephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023Nephros, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 08, 2023
공지 • Nov 16Nephros, Inc. announced delayed 10-Q filingOn 11/15/2022, Nephros, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Price Target Changed • Nov 16Price target decreased to US$3.63Down from US$4.13, the current price target is an average from 2 analysts. New target price is 241% above last closing price of US$1.06. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.63 next year compared to a net loss per share of US$0.41 last year.
Major Estimate Revision • Nov 09Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$10.5m to US$10.3m. Losses expected to increase from US$0.51 per share to US$0.63. Consumer Durables industry in the US expected to see average net income decline 15% next year. Consensus price target of US$3.63 unchanged from last update. Share price was steady at US$1.04 over the past week.
Reported Earnings • Nov 04Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.13 loss per share (further deteriorated from US$0.12 loss in 3Q 2021). Revenue: US$2.41m (down 8.6% from 3Q 2021). Net loss: US$1.33m (loss widened 8.6% from 3Q 2021). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 182%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, while revenues in the Consumer Durables industry in the US are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
공지 • Oct 12+ 2 more updatesNephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022Nephros, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022
Seeking Alpha • Sep 28Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operationNephros (NASDAQ:NEPH) has shipped 3,000 commercial water filters as part of its ongoing annual contract with Donastar Enterprises and Tractor Beverage in service of a national chain of fast-casual restaurants. “Earlier this year we established ourselves as an approved vendor for a national and widely recognized Quick Service Restaurant chain. The completion of this initial delivery is an important milestone in our continuing relationship, and a marker of success for the Nephros commercial water filtration business. The initial results of our partnerships with Donastar and Tractor are indicative of both positive momentum and high potential for additional national contracts. We look forward to developing even greater opportunities as our business relationships progress.” said Andy Astor, President and Chief Executive Officer.
공지 • Sep 10Nephros Appoints Joe Harris to Its Board of DirectorsNephros, Inc. announced the appointment of Joe Harris to its Board of Directors. Joe Harris is currently the Midwest, Sales Director at Murj. Previous positions have included East, Areas Sales Director at HeartFlow, Inc., Midwest Regional Sales Director at BIOTRONIK, and Regional Sales Manager at Boston Scientific. Joe is also a U.S. Army veteran. He received his B.S. in Systems Engineering Economics from the United States Military Academy at West Point, and his MBA in Marketing Finance from the University of Michigan.
공지 • Aug 24Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022On August 17, 2022, Wes Lobo, Chief Commercial Officer of Nephros, Inc. notified the Company that he is resigning his employment with the Company, to be effective no later than September 30, 2022.